These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36084538)

  • 1. Therapeutic efficacy of nivolumab plus sorafenib therapy in patients with unresectable hepatocellular carcinoma.
    Peng TR; Wu CC; Chang SY; Chen YC; Wu TW; Hsu CS
    Int Immunopharmacol; 2022 Nov; 112():109223. PubMed ID: 36084538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
    Wang W; Bai W; Wang E; Zhao Y; Liu L; Yang M; Cai H; Xia D; Zhang L; Niu J; Yin Z; Zhang Z; Fan D; Xia J; Han G
    Int J Cancer; 2017 Jan; 140(2):390-399. PubMed ID: 27681592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment.
    Lee CH; Lee YB; Kim MA; Jang H; Oh H; Kim SW; Cho EJ; Lee KH; Lee JH; Yu SJ; Yoon JH; Kim TY; Kim YJ
    Clin Mol Hepatol; 2020 Jul; 26(3):328-339. PubMed ID: 32460459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Child-Pugh B cirrhosis.
    Chapin WJ; Hwang WT; Karasic TB; McCarthy AM; Kaplan DE
    Cancer Med; 2023 Jan; 12(1):189-199. PubMed ID: 35652419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels.
    Hsu PY; Cheng TS; Chuang SC; Chang WT; Liang PC; Hsu CT; Wei YJ; Jang TY; Yeh ML; Huang CI; Lin YH; Wang CW; Hsieh MY; Hou NJ; Hsieh MH; Tsai YS; Ko YM; Lin CC; Chen KY; Dai CY; Lin ZY; Chen SC; Huang JF; Chuang WL; Huang CF; Yu ML
    Cancer Med; 2022 Jan; 11(1):104-116. PubMed ID: 34786871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
    Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
    J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.
    Bruix J; Cheng AL; Meinhardt G; Nakajima K; De Sanctis Y; Llovet J
    J Hepatol; 2017 Nov; 67(5):999-1008. PubMed ID: 28687477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
    Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
    BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.
    Edeline J; Blanc JF; Campillo-Gimenez B; Ma YT; King J; Faluyi O; Mathurin J; Ghazi S; Palmer DH; Meyer T
    Eur J Cancer; 2017 Nov; 86():135-142. PubMed ID: 28987770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review.
    Zhang X; Yang XR; Huang XW; Wang WM; Shi RY; Xu Y; Wang Z; Qiu SJ; Fan J; Zhou J
    Hepatobiliary Pancreat Dis Int; 2012 Oct; 11(5):458-66. PubMed ID: 23060390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
    Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
    J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study.
    Chen SC; Huang YH; Chen MH; Hung YP; Lee RC; Shao YY; Chao Y
    BMC Cancer; 2022 Jan; 22(1):55. PubMed ID: 35016637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib.
    Tsang J; Wong JSL; Kwok GGW; Li BCW; Leung R; Chiu J; Cheung TT; Yau T
    Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):589-598. PubMed ID: 33666530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Nakazawa T; Hidaka H; Takada J; Okuwaki Y; Tanaka Y; Watanabe M; Shibuya A; Minamino T; Kokubu S; Koizumi W
    Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):683-9. PubMed ID: 23395995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib.
    Yau T; Yao TJ; Chan P; Wong H; Pang R; Fan ST; Poon RT
    Oncologist; 2011; 16(9):1270-9. PubMed ID: 21885876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.
    Cosgrove DP; Reyes DK; Pawlik TM; Feng AL; Kamel IR; Geschwind JF
    Radiology; 2015 Nov; 277(2):594-603. PubMed ID: 26069923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma.
    Lee HJ; Lee JS; So H; Yoon JK; Choi JY; Lee HW; Kim BK; Kim SU; Park JY; Ahn SH; Kim DY
    Yonsei Med J; 2024 Jul; 65(7):371-379. PubMed ID: 38910299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review.
    Chou WC; Lee CL; Yang TS; Huang CY; Teng W; Tseng YT; Chen JS; Lin YC; Hou MM; Chang HH; Chia-Hsun Hsieh J
    J Formos Med Assoc; 2018 Feb; 117(2):153-163. PubMed ID: 28392193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular therapies for HCC: Looking outside the box.
    Faivre S; Rimassa L; Finn RS
    J Hepatol; 2020 Feb; 72(2):342-352. PubMed ID: 31954496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index.
    Ohki T; Kondo M; Karasawa Y; Kawamura S; Maeshima S; Kojima K; Seki M; Toda N; Shioda Y; Tagawa K
    Adv Ther; 2017 May; 34(5):1097-1108. PubMed ID: 28389996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.